The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Treatment-Resistant Hypertension Management Market Research Report 2025
Synopsis
The management of Treatment-Resistant Hypertension typically involves the use of multiple classes of antihypertensive medications, such as diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs).
Global Treatment-Resistant Hypertension Management market is projected to reach US$ 184.7 million in 2029, increasing from US$ 58 million in 2022, with the CAGR of 17.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Treatment-Resistant Hypertension Management market research.
The treatment-resistant hypertension management market is driven by the increasing prevalence of hypertension that does not respond to conventional antihypertensive treatments. Treatment-resistant hypertension refers to persistently high blood pressure despite the use of multiple medications. As the incidence of hypertension continues to rise, there is a growing need for effective management strategies to control blood pressure and reduce the risk of cardiovascular complications. The market is propelled by advancements in medical technology, the development of novel therapies, and a focus on individualized treatment plans. However, the market also faces challenges, including the complexity of managing multiple medications, potential side effects of advanced treatments, and the need for better patient compliance and adherence to therapies. To succeed in this market, healthcare providers and manufacturers must collaborate to develop innovative and patient-friendly treatment approaches that improve blood pressure control and enhance patient outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Treatment-Resistant Hypertension Management market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Janssen Biotech
Quantum Genomics
CinCor Pharma
Ionis Pharmaceuticals
Vifor Pharma
KBP Biosciences
Abbott
Kona Medical
Medtronic
Segment by Type
Diuretic Therapy
Combination Therapy
Mineralocorticoid Receptor Antagonists
Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Treatment-Resistant Hypertension Management report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
The management of Treatment-Resistant Hypertension typically involves the use of multiple classes of antihypertensive medications, such as diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs).
Global Treatment-Resistant Hypertension Management market is projected to reach US$ 184.7 million in 2029, increasing from US$ 58 million in 2022, with the CAGR of 17.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Treatment-Resistant Hypertension Management market research.
The treatment-resistant hypertension management market is driven by the increasing prevalence of hypertension that does not respond to conventional antihypertensive treatments. Treatment-resistant hypertension refers to persistently high blood pressure despite the use of multiple medications. As the incidence of hypertension continues to rise, there is a growing need for effective management strategies to control blood pressure and reduce the risk of cardiovascular complications. The market is propelled by advancements in medical technology, the development of novel therapies, and a focus on individualized treatment plans. However, the market also faces challenges, including the complexity of managing multiple medications, potential side effects of advanced treatments, and the need for better patient compliance and adherence to therapies. To succeed in this market, healthcare providers and manufacturers must collaborate to develop innovative and patient-friendly treatment approaches that improve blood pressure control and enhance patient outcomes.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Treatment-Resistant Hypertension Management market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Janssen Biotech
Quantum Genomics
CinCor Pharma
Ionis Pharmaceuticals
Vifor Pharma
KBP Biosciences
Abbott
Kona Medical
Medtronic
Segment by Type
Diuretic Therapy
Combination Therapy
Mineralocorticoid Receptor Antagonists
Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Treatment-Resistant Hypertension Management report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Treatment-Resistant Hypertension Management Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Diuretic Therapy
1.2.3 Combination Therapy
1.2.4 Mineralocorticoid Receptor Antagonists
1.3 Market by Application
1.3.1 Global Treatment-Resistant Hypertension Management Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Treatment-Resistant Hypertension Management Market Perspective (2018-2029)
2.2 Treatment-Resistant Hypertension Management Growth Trends by Region
2.2.1 Global Treatment-Resistant Hypertension Management Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Treatment-Resistant Hypertension Management Historic Market Size by Region (2018-2023)
2.2.3 Treatment-Resistant Hypertension Management Forecasted Market Size by Region (2024-2029)
2.3 Treatment-Resistant Hypertension Management Market Dynamics
2.3.1 Treatment-Resistant Hypertension Management Industry Trends
2.3.2 Treatment-Resistant Hypertension Management Market Drivers
2.3.3 Treatment-Resistant Hypertension Management Market Challenges
2.3.4 Treatment-Resistant Hypertension Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Treatment-Resistant Hypertension Management Players by Revenue
3.1.1 Global Top Treatment-Resistant Hypertension Management Players by Revenue (2018-2023)
3.1.2 Global Treatment-Resistant Hypertension Management Revenue Market Share by Players (2018-2023)
3.2 Global Treatment-Resistant Hypertension Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Treatment-Resistant Hypertension Management Revenue
3.4 Global Treatment-Resistant Hypertension Management Market Concentration Ratio
3.4.1 Global Treatment-Resistant Hypertension Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Treatment-Resistant Hypertension Management Revenue in 2022
3.5 Treatment-Resistant Hypertension Management Key Players Head office and Area Served
3.6 Key Players Treatment-Resistant Hypertension Management Product Solution and Service
3.7 Date of Enter into Treatment-Resistant Hypertension Management Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Treatment-Resistant Hypertension Management Breakdown Data by Type
4.1 Global Treatment-Resistant Hypertension Management Historic Market Size by Type (2018-2023)
4.2 Global Treatment-Resistant Hypertension Management Forecasted Market Size by Type (2024-2029)
5 Treatment-Resistant Hypertension Management Breakdown Data by Application
5.1 Global Treatment-Resistant Hypertension Management Historic Market Size by Application (2018-2023)
5.2 Global Treatment-Resistant Hypertension Management Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Treatment-Resistant Hypertension Management Market Size (2018-2029)
6.2 North America Treatment-Resistant Hypertension Management Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Treatment-Resistant Hypertension Management Market Size by Country (2018-2023)
6.4 North America Treatment-Resistant Hypertension Management Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Treatment-Resistant Hypertension Management Market Size (2018-2029)
7.2 Europe Treatment-Resistant Hypertension Management Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Treatment-Resistant Hypertension Management Market Size by Country (2018-2023)
7.4 Europe Treatment-Resistant Hypertension Management Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Treatment-Resistant Hypertension Management Market Size (2018-2029)
8.2 Asia-Pacific Treatment-Resistant Hypertension Management Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Treatment-Resistant Hypertension Management Market Size by Region (2018-2023)
8.4 Asia-Pacific Treatment-Resistant Hypertension Management Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Treatment-Resistant Hypertension Management Market Size (2018-2029)
9.2 Latin America Treatment-Resistant Hypertension Management Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Treatment-Resistant Hypertension Management Market Size by Country (2018-2023)
9.4 Latin America Treatment-Resistant Hypertension Management Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Treatment-Resistant Hypertension Management Market Size (2018-2029)
10.2 Middle East & Africa Treatment-Resistant Hypertension Management Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Treatment-Resistant Hypertension Management Market Size by Country (2018-2023)
10.4 Middle East & Africa Treatment-Resistant Hypertension Management Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Janssen Biotech
11.1.1 Janssen Biotech Company Detail
11.1.2 Janssen Biotech Business Overview
11.1.3 Janssen Biotech Treatment-Resistant Hypertension Management Introduction
11.1.4 Janssen Biotech Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.1.5 Janssen Biotech Recent Development
11.2 Quantum Genomics
11.2.1 Quantum Genomics Company Detail
11.2.2 Quantum Genomics Business Overview
11.2.3 Quantum Genomics Treatment-Resistant Hypertension Management Introduction
11.2.4 Quantum Genomics Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.2.5 Quantum Genomics Recent Development
11.3 CinCor Pharma
11.3.1 CinCor Pharma Company Detail
11.3.2 CinCor Pharma Business Overview
11.3.3 CinCor Pharma Treatment-Resistant Hypertension Management Introduction
11.3.4 CinCor Pharma Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.3.5 CinCor Pharma Recent Development
11.4 Ionis Pharmaceuticals
11.4.1 Ionis Pharmaceuticals Company Detail
11.4.2 Ionis Pharmaceuticals Business Overview
11.4.3 Ionis Pharmaceuticals Treatment-Resistant Hypertension Management Introduction
11.4.4 Ionis Pharmaceuticals Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.4.5 Ionis Pharmaceuticals Recent Development
11.5 Vifor Pharma
11.5.1 Vifor Pharma Company Detail
11.5.2 Vifor Pharma Business Overview
11.5.3 Vifor Pharma Treatment-Resistant Hypertension Management Introduction
11.5.4 Vifor Pharma Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.5.5 Vifor Pharma Recent Development
11.6 KBP Biosciences
11.6.1 KBP Biosciences Company Detail
11.6.2 KBP Biosciences Business Overview
11.6.3 KBP Biosciences Treatment-Resistant Hypertension Management Introduction
11.6.4 KBP Biosciences Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.6.5 KBP Biosciences Recent Development
11.7 Abbott
11.7.1 Abbott Company Detail
11.7.2 Abbott Business Overview
11.7.3 Abbott Treatment-Resistant Hypertension Management Introduction
11.7.4 Abbott Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.7.5 Abbott Recent Development
11.8 Kona Medical
11.8.1 Kona Medical Company Detail
11.8.2 Kona Medical Business Overview
11.8.3 Kona Medical Treatment-Resistant Hypertension Management Introduction
11.8.4 Kona Medical Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.8.5 Kona Medical Recent Development
11.9 Medtronic
11.9.1 Medtronic Company Detail
11.9.2 Medtronic Business Overview
11.9.3 Medtronic Treatment-Resistant Hypertension Management Introduction
11.9.4 Medtronic Revenue in Treatment-Resistant Hypertension Management Business (2018-2023)
11.9.5 Medtronic Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
